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Abstract—Goal: This paper reports a novel electromag-5
netic sensor technique for real-time noninvasive monitoring6
of blood lactate in human subjects. Methods: The technique7
was demonstrated on 34 participants who undertook a cy-8
cling regime, with rest period before and after, to produce a9
rising and falling lactate response curve. Sensors attached10
to the arm and legs of participants gathered spectral data,11
blood samples were measured using a Lactate Pro V2; tem-12
perature and heart rate data was also collected. Results:13
Pointwise mutual information and neural networks are used14
to produce a predictive model. The model shows a good15
correlation (R = 0.78) between the standard invasive and16
novel noninvasive electromagnetic wave based blood lac-17
tate measurements, with an error of 13.4% in the range of18
0–12 mmol/L. Conclusion: The work demonstrates that elec-19
tromagnetic wave sensors are capable of determining blood20
lactate level without the need for invasive blood sampling.21
Signiﬁcance: Measurement of blood metabolites, such as22
blood lactate, in real-time and noninvasively in hospital en-23
vironments will reduce the risk of infection, increase the fre-24
quency ofmeasurement and ensure timely intervention only25
when necessary. In sports, such tools will enhance training26
of athletes, and enable more effecting training regimes to27
be prescribed.28
Index Terms—Electromagnetic wave, microwave, non-29
invasive, point of care, sensor, wearable.30
I. INTRODUCTION31
LACTATE is key in two fundamental metabolic processes,32 glycolysis and oxidative phosphorylation, which serve as33
the basis for energy production in the human body [1]. Glycol-34
ysis is the process of converting glucose into the intermediate35
molecule pyruvate. Oxidative phosphorylation completes the36
process, in conjunction with oxygen, to form carbon dioxide;37
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both processes also result in the production of adenosine 38
triphosphate (ATP) which provides energy for cells to function. 39
When the body is in a resting and/or healthy non-active state, 40
lactate levels in the blood stream are maintained at a relatively 41
low steady state. According to Andropoulos [2], whole blood 42
lactate should be in the range 0.2–1.7 mmol/L in a healthy pa- 43
tient, with some variation noted based on age. However, when 44
stress is introduced to the body (e.g., via exercise or acute ill- 45
ness) the energy requirements of the body can alter signiﬁcantly. 46
Typically, glycolysis can accelerate rapidly to meet the new en- 47
ergy demand; however, oxidative phosphorylation does not. This 48
means that the body produces signiﬁcant amounts of pyruvate, 49
which it must then convert to lactate (via the enzyme lactate 50
dehydrogenase, or LDH) so that glycolysis can continue accel- 51
erating and producing both pyruvate and ATP. Once the lactate 52
level in the cells becomes saturated, it will be transported into 53
the blood stream; during acute exercise lactate may exceed 20 54
mmol/L, as shown by Goodwin et al [3] for example. In a 55
healthy person post-exercise, the lactate level will steadily drop 56
back to normal levels, with oxidative phosphorylation being able 57
to clear the excess lactate. 58
When the stress placed on the body is due to illness, the 59
tendency for the body to accumulate lactate is prolonged, per- 60
haps resulting in lactic acidosis. It is therefore commonplace 61
in contemporary medicine for lactate to be used as a means to 62
evaluate the severity of acute illness, diagnose disease states, 63
predict mortality, and assess response to resuscitation [4]. Fur- 64
thermore, in sport, lactate is one of the most often measured 65
parameters when performance testing athletes and prescribing 66
exercise intensities [3]. 67
Current off-the-shelf Point of Care (PoC) technologies (fur- 68
ther detailed in Section II) necessitate a blood sample. While 69
steps have been taken to speed up the process of measurement 70
and analysis, the requirement of extracting blood is still con- 71
sidered a major inconvenience. In a hospital environment, this 72
carries signiﬁcant infection control risks, and the frequency of 73
sampling is rarely sufﬁcient for clinicians to understand whether 74
intervention is necessary. Leading clinicians at Alder Hey Chil- 75
drensHospital (Liverpool, UK) suggest that even if patient blood 76
is sampled and measured 4–6 times per day, as may be the case 77
in intensive care environments, this does not readily enable one 78
to understand if the lactate level is rising (i.e., worsening condi- 79
tion) or falling (i.e., recovery). Furthermore, in cases where the 80
patient is an infant, the amount of blood available is small and 81
so extraction of even 1–3 ml of blood represents a signiﬁcant 82
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Fig. 1. (a) An example of a Siemens BGA used by the authors, with
capacity to measure and predict 24 different parameters based on an
input of approx. 0.1 ml of blood, and (b) a handheld Abott BGA offering
a greater level of portability and requiring 65 μL blood volume.
percentage of overall blood volume if sampling frequently and83
leads to considerable stress to the patient.84
For athletes, the issue of blood volume is less challenging85
since they are typically adult and in a good state of health. How-86
ever, blood sampling is still cumbersome in sport since athletes87
typically have to reduce exercise intensity (or stop altogether)88
to provide a measurement which prohibits continuous high res-89
olution monitoring during exercise.90
This paper describes the use of a microwave-based sensor for91
the measurement of lactate non-invasively by simple application92
to the skin of a subject. The authors have worked in this area for93
some years [5]–[9] mainly considering in-vitro measurement94
of lactate and the varying types of microwave-based sensor95
design depending on speciﬁc applications. This work takes a96
considerable step forward, and shows the potential of in-vivo97
application of the sensor technology with human participants in98
a controlled environment.99
II. STATE OF THE ART IN LACTATE MONITORING100
In a clinical environment blood gas analysis has become an101
integral part of patient monitoring, particularly in the case of102
acute illness (i.e., in emergency wards or intensive care units),103
with clinical staff relying upon inclusion of blood gas analysers104
(BGAs) to assist in diagnostic workups and development of105
treatment plans [10]. A BGA, such as that shown in106
Fig. 1(a), can directly measure pH, partial pressure of oxygen107
(PO2) and carbon dioxide (PCO2), a variety of electrolytes,108
and various metabolites including glucose, lactate, blood urea109
nitrogen, and creatinine [11]. Compared with laboratory anal-110
ysis, a BGA offers rapid measurement time (approx. 1 minute,111
excluding sampling and transit times) and a wealth of informa-112
tion upon which assessment of patient condition can be made.113
It is no surprise therefore that the BGA has become the gold114
standard against which clinicians compare emerging point of115
care technologies.116
Measurement with a BGA is not without its drawbacks how-117
ever, since the process of extracting blood from a patient is118
an invasive procedure, with potential complications which in-119
clude artery occlusion, digital embolisation leading to digital120
Fig. 2. Lactate Pro V2 LT–1730 in use by the authors.
ischemia, sepsis, local infection, pseudoaneurysm, hematoma, 121
bleeding, and skin necrosis [12]. As a result of infection risk, re- 122
source availability, and patient capacity to provide blood, BGA 123
does not give a high resolution assessment of patient condition 124
over time, which many clinicians argue would provide infor- 125
mation relevant to understanding the necessity and form of in- 126
tervention. Furthermore, the drive toward more point of care 127
monitoring equipment located at the patient bedside has clini- 128
cians looking toward smaller and more portable devices. Some 129
attempts to produce portable BGAs, such as the Abott i-STAT 130
device illustrated in Fig. 1(b), have been commercialised and 131
studies show they give levels of accuracy for lactate comparable 132
with larger desktop systems [13]. However, the required blood 133
volume (65 μL), long sampling times (approx. 65 seconds) and 134
skilled handling procedure preclude use at the bedside. 135
BGAs offer a broad range of measurements, but a number 136
of devices have been released to the market that offer sin- 137
gle metabolite measurement. These are typically based on an 138
electrochemical principle, using an electrochemically sensitised 139
strip which, when exposed to blood, changes its electrical prop- 140
erties. When inserted into a device designed to interface with 141
these strips, users are able to obtain a lactate reading within 142
15–60 seconds. While these devices still require blood to be ex- 143
tracted from a subject, the volume requirement is signiﬁcantly 144
lower than a BGA–for example the Lactate Pro V2 LT–1730 145
system (see Fig. 2) used regularly by the authors requires only 146
5 μL of blood. 147
An in-depth study [14] considered the reliability of such hand- 148
held electrochemical devices, concluding that although all de- 149
vices tested exhibited varying characteristic (error, accuracy), 150
all could be used for longitudinal studies and have particular 151
relevance in prescribing exercise regimes. A smaller study [15] 152
also demonstrated that such electrochemical sensors give ac- 153
ceptable results in clinical settings, and some are approved for 154
medical use, however there is little evidence to show signiﬁcant 155
uptake in this context. This is perhaps due to uncertainty re- 156
garding the unknown sources of error with point of care devices 157
(e.g., temperature, operator training, equipment condition, etc.) 158
when compared with clinical laboratory facilities [16], and the 159
remaining infection control risk due to extraction of blood, albeit 160
in smaller volumes. In addition, some caution against the use 161
of a ﬁngertip test for lactate due to inferior accuracy. Gaieski 162
et al. [17] note that this may not be an issue in all patients, 163
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Fig. 3. BSX Insight athlete lactate prediction system, (a) with sensor
removed from its wearable sleeve and (b) as worn by a cyclist.
but compares the case of those undergoing intensive care with164
those presenting at emergency departments. In the former case,165
patients will be given signiﬁcant volumes of intravenous ﬂuid166
which, coupled with continued capillary leak and decreased in-167
travascular osmotic pressure, can lead to diffuse tissue oedema168
[18]. In the latter case however, patients are often hypovolemic,169
potentially decreasing the amount of extravascular ﬂuid that170
enters a ﬁngertip blood sample.171
Devices such as the Lactate Pro and i-STAT represent the172
current state-of-the-art in terms portable point of care systems173
for determining absolute blood lactate, and work continues in174
this ﬁeld to improve cost, reliability and accuracy. A compre-175
hensive review of electrochemical sensor techniques to realise176
lactate measurement has been produced by Singh et al [19],177
and work by other researchers continues to improve this ﬁeld178
through new fabrication techniques andmethods tomove toward179
wearables, with researchers utilising sweat rather than blood for180
lactate measurements [20], [21]. The desire for devices to be181
wearable is well known across a range of blood metabolites, to182
remove completely the need for blood extraction and revolu-183
tionise healthcare practices.184
The options for non-invasive lactate monitoring remain lim-185
ited for practitioners in either healthcare or sports, and perhaps186
the best example to reach the market is the BSX Insight lactate187
prediction system (see Fig. 3). This is a validated [22] wear-188
able system to predict lactate threshold, the point at which the189
concentration of blood lactate begins to exponentially increase190
during exercise. This system uses near infrared (NIR) sensors191
to monitor oxygenation in the gastrocnemius muscle and, via192
a patented algorithm, detects inﬂection points in the muscle193
oxygenation curve at increased workloads.194
Other optical based techniques for monitoring lactate are ev-195
ident in the literature [23]–[27], however little of that work196
appears to have made a signiﬁcant presence on the PoC market.197
Largely speaking, these types of devices combine a chemical198
approach (e.g., a colour change) which then infers a lactate con-199
centration. However, these suffer from the same drawback as200
current electrochemical methods, namely the limited reusabil-201
ity of the sensitive elements of the device themselves. Boldt202
[16] demonstrates that costs from such point of care devices203
depend on many factors which can be categorised in terms of204
pre-analytical, analytical and post-analytical costs which may205
vary from one organisation to the next thus making the cost 206
beneﬁt difﬁcult to establish. 207
III. ELECTROMAGNETIC WAVE SENSORS 208
A review of the current state of the art reveals that techniques 209
available to practitioners in both clinical and sports contexts 210
present challenges for measuring lactate in real-time. Most 211
systems rely upon the extraction of blood, which presents in- 212
fection risks and is a barrier to providing high-resolution lactate 213
information. Furthermore, the single use model of portable 214
electrochemical PoC devices, such as the Lactate Pro and others 215
described in [14] pose challenges for clinical environments in 216
terms of budgeting and training. While there have been steps 217
to move toward wearable devices, those reported recently in 218
the research domain, particularly for monitoring sweat, have a 219
limited lifespan and therefore present similar issues. 220
Therefore, the authors have proposed the use of an electro- 221
magnetic (EM) wave sensor system, operating at microwave 222
frequencies, to provide a chemical-free sensor for real-time 223
monitoring of athletes. Although the main aim of the authors 224
has been to develop the system for medical use, it is clear 225
also that the technology has relevance to sport science, namely 226
the monitoring of athletes to ensure applicability of training 227
regimes, as well as to assist in their prescription. 228
EM wave sensors operating at microwave frequencies are 229
seeing an increasing interest across a variety of applications, 230
including for measurements in the food industry [28]–[31], for 231
water analysis [33], as well as for in-vitro, minimally-invasive 232
[36], [37] and non-invasive [38]–[40] medical purposes. The 233
sensors can typically be characterised as requiring low power 234
(< 1 mW) while retaining a good level of penetration into a 235
target material so that they may assess properties beneath a 236
surface–in this case, determination of blood lactate through the 237
skin of a subject. The sensors are also highly adaptable, with 238
cavities, ﬂuidic channels, ﬂexible and even fabric based devices 239
being demonstrated by researchers. It is these characteristics, 240
combined with their low-cost, that make them an interesting 241
proposition across so many potential application areas. 242
In this work, measurements from the EM wave sensor (de- 243
scribed in Section IV) are captured in the form of S-parameters 244
for reﬂected (S11) and transmitted (S21) energy. As energy is 245
coupled into the sensor, both the S11 and S21 signals vary de- 246
pending upon properties of the analyte presented to the sensor, 247
such as conductivity and permittivity [40]. Conductivity is a 248
measure of a material’s ability to conduct an electric current, 249
whereas permittivity is a measure of how an electric ﬁeld is af- 250
fected by a dielectric medium. This is determined by the ability 251
of a material to polarise in response to the ﬁeld, and reduce the 252
total electric ﬁeld inside the material. Therefore, permittivity 253
(εr) as deﬁned in (1) relates to a material’s ability to transmit 254
an electric ﬁeld and is a complex value which varies with fre- 255
quency, and accounts for both the energy stored by a material 256
(ε′) as well as any losses of energy (ε′′) which might occur. 257
εr = ε′ + jε′′ (1)
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The permittivity of a material is derived from a number of258
characteristics (e.g., temperature, chemical structure, molecu-259
lar composition, etc.) and is a measure of various polarisation260
phenomena that occur over different frequency ranges when261
exposed to an alternating EM ﬁeld [41]. This causes dipolar262
polarisation in polar molecules (such as lactate), which causes263
them to rotate over a time period proportional to their dipole264
moment and local conditions (e.g., viscosity). Since there is a265
delay between the dipolar polarisation and the applied alternat-266
ing EM ﬁeld, dispersions exist whereby the molecule does not267
have sufﬁcient time to fully align to the ﬁeld, giving rise to di-268
electric relaxation in the microwave region of the EM spectrum.269
Anumber of mathematical models have been developed by Cole270
and Cole [42], Cole and Davidson [43], [44] and Havriliak and271
Negami [49] to explain relaxation phenomena. It is based upon272
these principles that EM wave sensors, operating at microwave273
frequencies, can selectively detect molecules such as lactate.274
IV. METHODOLOGY275
This section of the paper describes the sensor used during276
the work, the testing regime employed using cyclists to test the277
sensor response to lactate levels, and detail regarding placement278
of the sensor itself on participants.279
A. Test Regime280
A testing regime was designed to enable the development of a281
lactate proﬁle in participants. The regime was based on the use282
of a Lode Excalibur Sport ergometer, which enables increase283
in pedal resistance up to 1500 W. The protocol adhered to was284
phased as follows:285
1) Begin with a rest period after ﬁtment of sensors and other286
preparation for 5minutes to enable stabilisation of a base-287
line lactate level;288
2) Warmup for a period of 5 minutes at 80 W, encourag-289
ing participants to maintain a constant cadence (approx.290
70-80 rpm) throughout;291
3) Increment resistance every 2 minutes by 20 W, maintain-292
ing similar cadence, and maintain resistance increment293
regime until cyclist cadence falls below 60 rpm, indicat-294
ing exhaustion.295
4) Conclude with a 10-minute rest period to observe falling296
lactate post-exercise.297
Throughout this test regime, measurements were taken with298
various devices as follows:299
1) EM wave sensor measurements, comprising an S11 and300
S21 spectra, every 30 seconds (see Sections IV-B and301
IV-C for detail of the sensor and placement).302
2) Blood lactate measurements using a Lactate Pro V2 elec-303
trochemical analyser, drawing blood samples from the tip304
of a ﬁnger on the left hand. In respect of the test regime,305
measurements were taken at the beginning and end of306
phase 1, the end of phase 2, every minute during phase 3,307
and then every 2 minutes during phase 4. This device was308
chosen not only due to its use in research work noted by309
other authors, but also due to it being one of the only such310
devices with medical approval.311
Fig. 4. The (a) top view and (b) bottom view of the physical sensor
used in this work, and (c) S-parameter measurements (10 MHz–4 GHz).
3) Temperature measurements using a thermocouple taped 312
to the arm and leg of participants. 313
4) Heart rate via a Polar V800 chest strap and watch com- 314
bination. 315
All data was date and time stamped so that it could be ret- 316
rospectively synchronised for comparison and analysis. Testing 317
took place between December 2015 and May 2016, with 34 318
participants being recruited for the trial. The majority of the 319
participants were male and aged between 25 and 40; 20% of 320
the test subjects were female. There is no signiﬁcant difference 321
noted in expected blood lactate levels in these groups [2]. In to- 322
tal, from all participants, 367 lactate measurements were taken 323
using the Lactate Pro V2 device, which acted as the reference 324
method in this study. 325
B. Electromagnetic Wave Sensor 326
For this work, a so-called hairpin resonator conﬁguration 327
of sensor has been designed and constructed as illustrated 328
in Fig. 4(a). The sensor dimensions are 40mm × 40mm × 329
1.6 mm (l × w × h), with coaxial (SMA) feeds to the decou- 330
pled hairpin conductors. 331
The sensor is manufactured via a standard etching process, 332
and the substrate is FR4 epoxy glass coated with a biocompati- 333
ble mask that helps to prevent leeching of the copper conductor 334
when worn by test subjects. The SMA connector contacts, 335
shown as exposed in Fig. 4(a) were also masked with insulating 336
tape when in use to prevent direct conductor contact with the 337
skin. The rear of the sensor has a discontinuous ground plane 338
that isolates ports 1 from port 2, as pictured in Fig. 4(b). This 339
is to enable resonance of the device, while also ensuring that 340
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the generated EM energy is directed toward the test material341
and providing the hairpin pattern with shielding from outside342
sources of interference.343
S-parameter measurements for the sensor in air are illustrated344
in Fig. 4(c), showing that the senor tends to resonate at approx.345
2 GHz. The sensor is designed such that the EM ﬁeld closely346
coupled to the surface of the sensor, so that the ﬁeld may pen-347
etrate through the skin of a target and interact with the ﬂuids348
beneath.Maintaining a ﬁeld close to the sensor surface has some349
advantages, namely that of reducing interference from objects350
other than the surface to which it is directly attached. The hair-351
pin conﬁguration of the device supports this notion well, and352
has the primary reason for its use.353
Each sensor was connected to a separate Rohde and Schwarz354
ZVL13 Vector Network Analyser (VNA), and S11 and S21355
measurements were recorded every 30 seconds via a bespoke356
LabView interface. The equipment was conﬁgured to capture357
data between 10MHz and 4 GHz, with 4000 discrete data points358
recorded. The equipment was set to output 0 dBm (1 mW)359
power. The system conﬁguration was selected based upon dis-360
cussion with the project partners, as well as knowledge obtained361
in prior published (e.g., [5], [6], [8], [39]) and unpublished362
work. Previous work suggested that lactate and similar metabo-363
lites were quantiﬁable within this selected frequency range,364
although some uncertainty of the precise response frequency365
was present due previous work being ex-situ. From a commer-366
cial perspective, it was desirable to have an upper limit of 4367
GHz to limit unit cost and size of a future “all-in-one” wearable368
solution.369
C. Sensor Placement370
The sensor was placed on the left arm and leg of each partici-371
pant; the leg due to this being the source of lactic acid production372
during exercise, and the arm due to blood being drawn from the373
ﬁnger tip for lactate measurement. Speciﬁc placement on the374
leg was over the Rectus femoris muscle and on the wrist approx.375
one-third distance between the wrist and elbow joints, where376
there would be signiﬁcant blood ﬂow owing to the Arteriove-377
nous ﬁstula. The left side of each participant was chosen simply378
due to accessibility within the testing space itself; the setup is379
shown in Fig. 5(a), with a closer view of the sensors adhered to380
a participant in Fig. 5(b).381
The sensors were ﬁxed to the participant using 75mm ×382
100 mm surgical dressings, modiﬁed by cutting to allow the383
right-angled SMA connectors to protrude. Cables were secured384
to the limbs of the participant using a surgical tape, primarily385
for mechanical strength. Prior to placement, the sensor and area386
under test was cleansed with an alcohol wipe. No shaving or387
other preparation of the skin was undertaken.388
V. RESULTS AND DISCUSSION389
With 34 participants and a total of 367 blood lactate mea-390
surements, on average there were 11 blood samples taken per391
participant. Naturally, this varied depending on the ﬁtness level392
of participants, and thus their ability to maintain a steady ca-393
dence despite the increasing work rate. Fig. 6 gives an indicative394
Fig. 5. (a) Experimental setup, with participant on ergometer and sen-
sors attached to data acquisition hardware; (b) illustrates placement of
sensors on both arm and leg with another participant.
Fig. 6. Illustrating the test regime implemented, as described in
Section IV.
lactate proﬁle, with markers denoting the four phases discussed 395
in the methodology section. 396
Separating the collected data into the groups 0–5 (48.2%), 397
6–10 (22.1%), 11–15 (26.3%) and >16 (5.8%) by lactate con- 398
centration (in mmol/L) gave an indication of data distribution. 399
The majority of data collected is in the range of 0–5 mmol/L, 400
with an approximately even split then between the 6–10 and 401
11–15 mmol/L groups. This is reasonable given participants 402
would spend 5 minutes resting at the beginning and end of the 403
resting regime, and a further 5 minutes warming up with little 404
exertion (for most) experienced in this period. Few participants 405
were able to raise their lactate level above 15 mmol/L, and so 406
the data availability > 15 mmol/L for the purposes of creating 407
relevant models linking EM sensor output with actual lactate 408
level is limited. 409
A number of techniques were considered for providing robust 410
analysis and models to test the correlation between EM wave 411
sensor outputs and lactate level measured via Lactate Pro V2. 412
Typical linear models, which have proven successful for in-vitro 413
laboratory based tests (for example, see previous work of the 414
authors in this ﬁeld [5]–[9]) yielded relatively low correlation 415
across the complete data set. 416
Therefore, for this work, the authors applied the approach 417
of Pointwise Mutual Information (PMI), combined with Neural 418
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Networks (NNs). PMI is a useful method for establishing the re-419
lationship between datasets and their supposed target data, and420
producing rankings that indicate the prominence of relation-421
ships. In this work, PMI was used to consider the relationship422
between the lactate value measured with the Lactate Pro V2,423
and the corresponding spectral data captured using the EMwave424
sensor. By doing this, it was possible to rank the spectral data425
by frequency in order of its relevance, and therefore reduce the426
spectral dataset being provided to the NN. This has signiﬁcance427
for two reasons since: 1) it reduces the amount of irrelevant428
information being provided to the NN, thereby improving the429
likelihood of a suitable model being generated and; 2) it assists430
in the commercial objectives of the work since limiting the fre-431
quency of operation reduces cost, size and power requirements,432
all of which are barriers to implementing a wearable system.433
A number of reduced datasets were produced using the PMI434
method, based on the top 10, 20, 50, 100, 250 and 500 frequen-435
cies of interest per measurement with the EM sensor, where436
originally data was acquired at 4000 discrete frequencies be-437
tween 10MHz and 4GHz. This was replicated for data collected438
from both the arm and leg of each participant, as well as for each439
measurement mode, i.e., S11 and S21 .440
The NN approach was applied in Mathworks MatLab soft-441
ware for each dataset. The data was split into a training set442
(225 values, 65%), validation set (75 values, 22%) and test set443
(45 values, 13%). Splitting of the data was performed at random444
and 10-fold cross validation was performed. It is noted that the445
volume of data available for lactate levels exceeding 15 mmol/L446
is limited and so this part of the dataset was excluded from447
this machine learning exercise. Thus, the total number of lactate448
measurements available was reduced from 367 to 345. Results449
corresponding to each mode of measurement (i.e., S11 or S21),450
each location (i.e., arm or leg) and each frequency ranking (i.e.,451
10, 20, 50, 100, 250 and 500) were recorded, and are shown452
in Table I. On average, the best performing measurement was453
achieved with the sensor located on the arm, and with the S11454
mode of measurement; this consistently achieves an Rtest >455
0.75 once the number of discrete frequencies used for training456
approaches or exceeds 100. Typically speaking, the results pro-457
duced from theNNmodelling indicate that once 100 frequencies458
of interest are exceeded, there is a little relative improvement459
in model performance with further increase in the number of460
frequencies–this is evident in the plateau effect for both R and461
RMSE shown in Fig. 7.462
Themeasurements conducted on the leg, also in theS11 mode,463
tend to give next best performance, achieving an R-value of ap-464
prox. 0.7 with 100 frequencies of interest fed into the training465
model. It is noted that the error in this case is reported to be466
higher, which is thought to be a result of the sensor (and par-467
ticularly the cables) moving during the exercise, which increase468
noise apparent in the acquired data. A better mechanical ﬁt of469
the sensor to the skin might resolve such issues, as might the470
future integration of the electronics into an all-in-one wearable471
device, which would completely remove the need for cables.472
Fig. 8(a) illustrates the training model created for the top473
100 ranked frequencies of interest using the S11 arm combina-474
tion, which tended to be most signiﬁcantly concentrated in the475
TABLE I
NEURAL NETWORK TRAINING AND TEST R AND RMSE VALUES FOR EACH
MODEL CREATED ACROSS THE MEASUREMENT MODES, LOCATIONS AND
NUMBER OF TOP RANKED FREQUENCIES FROM THE INPUT DATASET
No. Data S11 S21 S11 S21
Freq Type Arm Arm Leg Leg Ave.
10 Rtra in in g 0.8719 0.7191 0.7669 0.7252 0.7708
R t e s t 0.5543 0.4268 0.5936 0.3682 0.4857
RMSEtra in in g 2.0721 2.9301 2.7149 2.9213 2.6596
RMSEte s t 4.4068 4.1791 3.7223 4.7677 4.2690
20 Rtra in in g 0.8311 0.8897 0.8140 0.7998 0.8337
R t e s t 0.5267 0.2213 0.6107 0.2734 0.4080
RMSEtra in in g 2.3543 1.9321 2.4589 2.5413 2.3217
RMSEte s t 4.775 5.6949 3.7047 5.4118 4.8966
50 Rtra in in g 0.9529 0.8424 0.9245 0.8016 0.8804
R t e s t 0.6456 0.50900 0.7060 0.5160 0.5942
RMSEtra in in g 1.2949 2.2721 1.6149 2.5297 1.9279
RMSEte s t 4.0165 4.0477 3.8603 4.278 4.0506
100 Rtra in in g 0.9653 0.9225 0.8571 0.9469 0.9230
R t e s t 0.7827 0.3274 0.7270 0.2575 0.5237
RMSEtra in in g 1.1087 1.6316 2.1857 1.3698 1.5740
RMSEte s t 2.8786 5.1848 3.081 8.7872 4.9829
250 Rtra in in g 0.9486 0.9607 0.9247 0.9765 0.9526
R t e s t 0.8047 0.4747 0.5700 0.3718 0.5553
RMSEtra in in g 1.3589 1.1724 1.625 0.9148 1.2678
RMSEte s t 2.7426 4.8635 4.6707 5.4387 4.4289
500 Rtra in in g 0.9163 0.9589 0.7968 0.9606 0.9082
R t e s t 0.7632 0.5449 0.6871 0.3945 0.5974
RMSEtra in in g 1.7621 1.228 2.5578 1.2061 1.6885
RMSEte s t 3.242 5.0805 3.2657 5.743 4.3328
Ave. Rtra in in g 0.9144 0.8822 0.8473 0.8684 -
R t e s t 0.6795 0.4174 0.6491 0.3636 -
RMSEtra in in g 1.6585 1.8611 2.1929 1.9138 -
RMSEte s t 3.6769 4.8418 3.7175 5.7377 -
Fig. 7. Average R and RMSE values for all modes of measurement vs.
number of frequencies used to create a prediction model.
Fig. 8. Correlation for the top 100 frequencies selected via the PMI
method for S11 arm; (a) training model and (b) test data ﬁt in the range
0-15 mmol/L
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3.4–3.6 GHz region of the measured spectra. It is noted that the476
RMSE reported for the test data (see Table I) is typically higher477
than that for the training mode, which is to be expected with NN478
methods.479
The data contained in Table I is relevant for the range480
0–15 mmol/L, based upon the categories used to represent the481
distribution of lactate values collected. The best performing482
combination of sensor position and measurement mode in this483
study was the S11 arm combination, which in part is thought484
to be a result of the arm location having little movement dur-485
ing the experimentation. Using the top 100 ranked frequen-486
cies, the training model error is 7.4%, and the test error 19.2%487
in the range 0–15 mmol/L. However, Fig. 8(b) demonstrates488
that the NN model does not perform well at lactate levels >12489
mmol/L; in the range 0–12 mmol/L the test error is reduced490
to 13.4%.491
It is planned to conduct further trials to augment the current492
collected data, which it is hoped will reduce the sensor error493
at higher lactate levels. Trial of the sensor on athletes for ex-494
ample will assist in this, since they will be able to maintain495
high lactate levels for longer and therefore provide more data496
in the range >12 mmol/L. Ideally this additional data collec-497
tion should be coupled with the earlier suggestions regarding498
improved mechanical ﬁt of the sensor to the skin.499
A parallel study, conducted by the authors at Alder Hey Chil-500
dren’s Hospital to assess the expected levels of blood lactate501
in patients undergoing intensive care, found that only 0.87% of502
blood samples reported a lactate concentration >12 mmol/L.503
This was based on 1,000 blood samples taken over a 3 month504
period and measured using the standard BGA method. This505
therefore suggests that the sensor, even in its current form, can506
report clinically relevant information.507
A major beneﬁt of real-time on-patient monitoring noted ear-508
lier was the potential to be able to monitor live patient informa-509
tion. Current blood sampling does not give enough resolution to510
understand whether a patient’s lactate level is rising or falling,511
and therefore deciding on an intervention strategy can be chal-512
lenging. Thus, being able to track the direction of lactate change513
is perhaps as important as knowing its absolute value. The capa-514
bility of the sensor to do this is illustrated in Fig. 9, where all of515
the collected data from the 34 participants is overlaid with the516
predicted data from the NN model, trained using 100 discrete517
frequencies.518
Temperature and heart rate were measured in this study to519
understand if they inﬂuenced the sensor output. It is known that520
temperature is crucial in the use of EM wave devices, particu-521
larly due to the resultant change in εr [46]. During this study,522
it was noted that the average absolute skin temperature varia-523
tion between the end of phase 1 and beginning of phase 4 was524
2.28 °C (min 0.92 °C, max 4.30 °C). It was also noted that the525
temperature recorded by the thermocouple sensors tended to fall526
during exercise, most likely due to participant perspiration [47].527
Heart rate on the other hand, tended to rise as work output in-528
creased from a resting average of 85 bpm to a maximum of 172529
bpm. Notably however, whereas heart rate tended to fall almost530
immediately post-exercise, lactate level would continue to rise531
due to the latency inherent in lactate metabolism. As a result,532
Fig. 9. Actual data measured vs. neural network model, highlighting
the capability of the model to predict the lactate proﬁle, not only absolute
value.
both temperature and heart rate failed to yield a signiﬁcant cor- 533
relation with the EM wave sensor measurements, with R < 0.4 534
in both cases. This adds further weight to the previously dis- 535
cussed correlation between the EM wave sensor and blood lac- 536
tate, as it shows that other parameters such as temperature and 537
heart rate do not signiﬁcantly inﬂuence the sensor. 538
VI. CONCLUSION 539
This work has demonstrated the novel application of an 540
EM wave sensor for the non-invasive real-time monitoring of 541
blood lactate, as correlated with the well-known Lactate Pro V2 542
electrochemical analyser. In total 34 participants, generating a 543
dataset of 367 blood lactatemeasurements, took part in the study 544
through a static cycling test regime designed to promote a trace- 545
able blood lactate proﬁle. Using a PMI method to reduce the 546
necessary dataset acquired from the sensor, and a NN machine 547
learning algorithm to create a predictive model, it was demon- 548
strated that a reliable correlation (R = 0.78) could be obtained 549
when the sensor was conﬁgured in the S11 measurement mode, 550
and located on the arm of the test subjects. In the range 0–12 551
mmol/L lactate, the sensor was shown to have an error of 13.4%. 552
In addition, it was demonstrated that this model has relevance 553
in not only predicting absolute lactate values, but also tracking 554
their direction for the purposes of, for example, prescribing pa- 555
tient interventions. Furthermore, it was shown that participant 556
temperature and heart rate did not have a signiﬁcant inﬂuence 557
on the results. This work therefore shows the potential for EM 558
wave sensors as PoC systems. Future work in this area will fo- 559
cus on two areas: (1) the collection of further data to improve 560
the predictive model and; (2) the improvement of the sensor 561
design toward an “all-in-one” wearable solution. The present 562
study has provided useful information in this regard, since the 563
best performance was noted in the S11 measurement mode, and 564
in the range of 3.4–3.6 GHz. This information will enable re- 565
duction of the number of cables (and the associated electronics) 566
required for a commercial solution, in addition to focusing ef- 567
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forts to enhance the sensor design in the noted frequency range568
for improved sensitivity and robustness of measurement, as well569
as a reduction in sensor size.570
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